{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:10:42Z","timestamp":1790003442661,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ygyno.2016.07.112","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T17:27:21Z","timestamp":1471886841000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2"],"prefix":"10.1016","volume":"143","clinical-trial-number":[{"clinical-trial-number":"nct01204749","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk-Soo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lhomm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores Gallardo","family":"Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arija","family":"Brize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-4777","authenticated-orcid":false,"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian D.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.07.112_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fon.13.206","article-title":"Optimizing treatment of the partially platinum-sensitive ovarian cancer patient","volume":"9","author":"Colombo","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2010.07.016","article-title":"A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites","volume":"79","author":"Barni","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","article-title":"Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures","volume":"4","author":"Sangisetty","year":"2012","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0025","doi-asserted-by":"crossref","first-page":"15885","DOI":"10.3390\/ijms140815885","article-title":"Angiogenesis-related pathways in the pathogenesis of ovarian cancer","volume":"14","author":"Gavalas","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0030","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/BF03402191","article-title":"Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays","volume":"6","author":"Martoglio","year":"2000","journal-title":"Mol. Med."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0035","first-page":"3403","article-title":"Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000065066","article-title":"Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer","volume":"62","author":"Hata","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0045","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/1471-2407-14-696","article-title":"Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer","volume":"14","author":"Sallinen","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0055","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2015.01.005","volume":"137","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0065","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0070","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0075","first-page":"PL01","article-title":"AGO-OVAR 12: a randomized placebo-controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy\u00b1nintedanib for advanced ovarian cancer [abstract]","volume":"23","author":"Du Bois","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0080","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0085","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0090","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","article-title":"Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2","volume":"6","author":"Oliner","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","article-title":"Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Monk","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0105","series-title":"Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer","author":"Raspagliesi","year":"2014"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0115","author":"Cancer Therapy Evaluation Program"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0125","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0130","series-title":"Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics","author":"US Department of Health and Human Services","year":"2007"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0135","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0140","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","article-title":"Ovarian cancer clinical trial endpoints: society of Gynecologic Oncology white paper","volume":"132","author":"Herzog","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0150","series-title":"Appendix 1 to the Guideline on the Evaluation of Anticancer Medicinal Products in man","author":"European Medicines Agency","year":"2012"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0155","article-title":"Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum resistant recurrent ovarian cancer (OC) [abstract]","volume":"49","author":"Witteveen","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.07.112_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG oncology\/GOG study","volume":"139","author":"Ferriss","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0165","first-page":"1553","article-title":"Malignant ascites in ovarian cancer and the role of targeted therapeutics","volume":"34","author":"Smolle","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/gyno.1996.0106","article-title":"The prognostic implication of ascites in advanced-stage ovarian cancer","volume":"61","author":"Puls","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","article-title":"Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Gotlieb","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2011.11.021","article-title":"A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites","volume":"125","author":"Colombo","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.07.112_bb0185","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ygyno.2013.05.023","article-title":"Incidence and management of edema associated with trebananib (AMG 386)","volume":"130","author":"Monk","year":"2013","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816309830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816309830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T14:53:03Z","timestamp":1668610383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816309830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0090825816309830"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.112","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726665053.793527327","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}